• 药物研究 • 上一篇 下一篇
黄亚芳,谢文杰
收稿日期:
修回日期:
出版日期:
发布日期:
基金资助:
HUANG Ya-fang and
Received:
Revised:
Online:
Published:
摘要: 本文回顾性剖析了抗癌药Ⅰ期临床试验的相关概念实质,阐明传统“3+3”剂量爬坡设计的局限及连续重评估方法(Continual reassessment method,CRM)的优势,对Ⅰ期临床试验中基于单参数功效模型的CRM、贝叶斯模型平均CRM、数据增强CRM、时间-事件CRM、分数CRM及其应用分别进行了详细解析,最后就CRM的试验设计流程进行了系统性概括,旨在为我国抗癌药Ⅰ期临床试验设计的方法学提供参考。
Abstract: This article briefly introduced the aim and concept of phase Ⅰ clinical trial for anti-cancer drugs. We analyzed and pointed out the disadvantages of traditional “3+3” design and the advantages of continual reassessment method (CRM) for dose-escalation trial. Then we introduced in detail the concept and application of CRM, including the CRM based on single skeleton, Bayesian model averaging CRM, data augmentation CRM, time-to-event CRM and fractional CRM for phase Ⅰ trial. In the end, we described the trial design process using the CRM. The information in this article we provide is aimed at clinicians and sponsors for their methodological references of phase Ⅰ trial design of anti-cancer drugs in China.
黄亚芳,谢文杰. 抗癌药Ⅰ期临床试验连续重评估方法解析及应用[J]. .
HUANG Ya-fang and. An Introduction of Continual Reassessment Method and Its Application in Phase Trial for Anti-cancer Drug[J]. .
0 / / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: http://www.zgywpj.cn/CN/
http://www.zgywpj.cn/CN/Y2019/V36/I1/46